Supplementary Table S2 from Health Disparities among Patients with Cancer Who Received Molecular Testing for Biomarker-Directed Therapy

Elisabeth I. Heath(The Barbara Ann Karmanos Cancer Institute), John L. Marshall(Vince Lombardi Cancer Clinic), Jennifer R. Ribeiro(Women & Infants Hospital of Rhode Island), Samuel A. Kareff(University of Miami), Hirva Mamdani(Wayne State University), Ralph J. Hauke(Canadian Cancer Society), Ira Winer(The Barbara Ann Karmanos Cancer Institute), Jailan A. Elayoubi(The Barbara Ann Karmanos Cancer Institute), Mohammed Najeeb Al Hallak(The Barbara Ann Karmanos Cancer Institute), Milan Radovich(Caris Life Sciences (United States)), Gary A. Puckrein(National Quality Forum), Frank C. Cackowski(Wayne State University), George W. Sledge(Caris Life Sciences (United States)), Gilberto Lopes(University of Miami), Anthony F. Shields(Wayne State University), Gregory A. Vidal(West Cancer Center), Joanne Xiu(Caris Life Sciences (United States)), David Spetzler(Caris Life Sciences (United States)), Gregory Dyson(The Barbara Ann Karmanos Cancer Institute), Nathaniel Jones(USA Mitchell Cancer Institute), Kelsey Poorman(Caris Life Sciences (United States))
Unknown
October 4, 2024
10.1158/2767-9764.27169559
Cited by 0

Related Papers

Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade
|Science|2017|6.6k
Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial
|The Lancet|2019|3.3k
3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)
|Annals of Oncology|2016|2.1k
Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study
|The Lancet|2020|1.8k
MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2− Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy
|Journal of Clinical Oncology|2017|1.7k